Investment Considerations Tryp Therapeutics is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications. The company is targeting diseases with few existing treatments options for patients that represents more than $12 billion in annual sales potential. Tryp is initiating multiple Phase 2a clinical trials … Continue reading “Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |